Finance Foggle

  Key Takeaways S&P 500 Entry : Block (formerly Square) joins the S&P 500 on  July 23, 2025 , replacing Hess after its acquisition by Chevron . Market Reaction : Block’s stock surged  >10%  post-announcement as funds rebalanced portfolios to include it . Challenges Persist : Despite the boost, Block’s 2025 performance remains  down 14%  YTD due to weak Q1 results and tariff-related macro concerns . Strategic Significance : Entry validates Block’s pivot to blockchain/fintech and accelerates crypto’s mainstream adoption . Next Catalyst : Q2 earnings on  August 7  will test whether S&P-driven demand offsets economic headwinds . The Big News: Block Is Joining the S&P 500 Come July 23rd, Block—y’know, the company behind Square and Cash App—steps into the S&P 500. They’re takin’ Hess’s spot, which is exitin’ after Chevron wrapped up that $54 billion buyout. Hess had some juicy oil assets down in Guyana, but Chevron finally closed ...

Key Takeaways FDA Requests Shipment Halt : The FDA plans to ask Sarepta to voluntarily stop all Elevidys shipments, expanding beyond non-ambulatory patients . Third Patient Death : A 51-year-old man died of acute liver failure in a Sarepta limb-girdle muscular dystrophy trial, following two teen Duchenne patient deaths. Stock Collapse : Sarepta’s shares fell 36% to a nine-year low, erasing ~$8.5B in market value since March. Management Controversy : Executives face criticism for not disclosing the third death during a restructuring announcement. Patient Dilemma : Families balancing hope for Duchenne treatment against liver failure risks. The FDA’s Unprecedented Move Against Elevidys What’s happening right now? The U.S. Food and Drug Administration (FDA) is preparing to formally request that Sarepta Therapeutics voluntarily halt  all  shipments of its gene therapy Elevidys, according to insider sources. This isn’t just targeting non-ambulatory patients—Sarepta already paused th...

Key Takeaways The Gen Z stare manifests in two primary forms : a vacant expression from service workers during perceived unreasonable customer interactions ( customer service stare ) and from Gen Z customers instead of verbal responses ( customer stare ) . Pandemic isolation critically impacted social skill development : Reduced face-to-face interaction during formative years limited practice with conversational norms and non-verbal cues for many Gen Zers . It’s often misinterpreted as rudeness or disinterest : Older generations may perceive the stare as disrespectful, while Gen Z frequently views it as a legitimate response to inauthentic or inefficient interactions . Underlying factors include heightened anxiety and authenticity values : Gen Z prioritizes genuine communication and may reject performative politeness, while also experiencing higher rates of social anxiety . Workplaces are adapting training programs : Organizations recognize gaps in soft skills like interpersonal commun...

  Key Takeaways: The GENIUS Act Becomes Law First Major Crypto Law:  Trump signed the GENIUS Act on July 18, 2025, establishing the first federal regulatory framework for stablecoins . Stablecoin Rules:  Requires 100% reserves (cash/short-term Treasuries) and monthly public disclosures from issuers. Prioritizes consumer claims if issuers fail . Political Win:  Passed with bipartisan support (Senate 68-30, House 308-122) after Trump intervened to sway GOP holdouts . Dollar Dominance Goal:  Aims to boost demand for U.S. debt and cement the dollar’s global reserve status by tying stablecoins to dollars/Treasuries . Controversies:  Critics cite potential conflicts of interest (Trump family’s crypto ventures) and warn consumer protections are too weak . Industry Boost:  Part of a "Crypto Week" that also passed the CLARITY Act and Anti-CBDC Surveillance Act . What Just Happened With Crypto Law? So yeah, President Trump signed this big deal crypto bill called...

  Key Takeaways Coca-Cola's potential switch  to cane sugar follows political pressure but faces  economic hurdles  . Price disparity : High-fructose corn syrup costs  $0.35/lb  vs. cane sugar at  $1.01/lb —nearly triple. Farm impact : Eliminating corn syrup could wipe out  $5.1B in U.S. farm revenue  . Health equivalence : The FDA states  no nutritional difference  exists between the sweeteners . Consumer cost : Mexican Coke (cane sugar) costs  over 60% more  than U.S. corn-syrup versions . The President’s Truth Social Bombshell President Trump fired a post into the digital ether. He claimed Coca-Cola agreed to dump high-fructose corn syrup for "REAL Cane Sugar" in U.S. products. The announcement hit like a barstool declaration—loud, abrupt, short on details. Coca-Cola’s response? A terse nod to "new innovative offerings." No confirmation. No timeline. Just corporate speak wrapped in a question mark. The disconnect betwee...

  Key Takeaways President Trump signed the  GENIUS Act , establishing the first U.S. regulatory framework for stablecoins . The law mandates  1:1 dollar reserves  for stablecoin issuers, aiming to legitimize crypto payments . Corporate giants like  Uber ,  Shopify , and  Apple  are exploring stablecoin integration . Critics warn the rules are  too weak  and could enable illicit finance . Trump’s family benefits directly through their venture  World Liberty Financial  . The GENIUS Act Hits the President’s Desk Trump scrawled his name on the bill Friday in the East Room. He joked about the acronym. “They named it after me.” The GENIUS Act— Guiding and Establishing National Innovation for U.S. Stablecoin —cleared the House 308-122. It sailed through the Senate last month. The law demands stablecoin issuers hold cash or Treasuries matching their tokens dollar-for-dollar. No more printing smoke. SEC Chair Paul Atkins called it a “hi...

  Key Takeaways Private insurers denied 22.9% of prescription claims in 2023—a 25% surge since 2016 . Cigna ,  Aetna , and  UnitedHealthcare  led denials, rejecting 1 in 4 prescriptions . Insurers hide denial reasons, creating a "black box" for patients and doctors . AI claims processors and costly GLP-1 drugs (e.g., Ozempic) drive the spike . Initial denials often stand—UnitedHealthcare’s “resubmission” argument ignores patient burnout . The Denial Machines Churn Harder The pills pile up at pharmacy counters. Lipitor. Insulin. Ozempic. Bottles with child-proof caps lined up like soldiers. Patients shuffle feet. Pharmacists tap keyboards. Then the hum:  denied . Private insurers now reject  22.9%  of prescription claims—a  25% jump  from 2016’s 18.3%. Komodo Health tracked this over  4 billion claims . The machines digest numbers. Spit out “no” . The Corporate Architects Names you know.  Cigna .  Aetna .  UnitedHealthcare ...

  Key Takeaways Sarepta Therapeutics stock plunged ~40% following a second patient death linked to its gene therapy Elevidys . FDA may pull Elevidys off the market as safety concerns mount; shipments halted for non-ambulatory patients . Therapy initially approved controversially in 2023 for ages 4-5, later expanded amid efficacy debates . Year-to-date stock loss exceeds 87%, erasing billions in market value . Duchenne muscular dystrophy patients face renewed uncertainty as treatment risks outweigh benefits for some . The Bloodbath on Nasdaq Sarepta Therapeutics stock cratered 40% in premarket trading June 16, 2025. It opened at $13.60—a far cry from its 52-week high of $150.48 . The collapse wasn't a surprise to those watching the ticker. Shares had been dying a slow death all year. By July, the year-to-date loss hit 87.5% . Shareholders stared at ruins. Trading volume exploded to 60 million shares. Average volume is 5.9 million . The market cap vaporized—$1.336 billion intraday. D...